Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Merck's vintafolide fails ovarian cancer trial

Merck's vintafolide fails ovarian cancer trial. Major blow for drug’ s original developers Endocyte. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last 12 months.

Latest news

EMA backs Janssen rare disease drug for approval

it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs
Boehringer/Lilly's empagliflozin among CHMP recommendations

There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).
Late-stage ovarian cancer

Endocyte's vintafolide is a folate-targeted conjugate composed of a folate molecule plus a vinca alkaloid, which acts as a microtubule destabilising agent. ... Phase III studies of vintafolide for the treatment of platinum-resistant ovarian cancer are
Merck's vintafolide shows its worth in ovarian cancer

unlikely to be superior to docetaxel alone, caused a massive reduction in the shares of Endocyte, the US firm which originally developed it. ... Along with Merck, Endocyte has been "building up our commercial capabilities to prepare for a potential
AZ licenses Merck ovarian cancer drug

vintafolide for ovarian cancer, which Merck licensed from Endocyte last year in a deal valued at up to $1bn.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Charting a course for expansion

and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

Endocyte appoints Parexel's Scot Harper to oversee clinical trials. He also previously served at Novartis and Lilly. ... In addition, Endocyte says it has three new drug candidates scheduled to enter the clinic before the end of 2014.
Endocyte brings in senior figures from BMS and Amgen

Endocyte brings in senior figures from BMS and Amgen. Appoints Torsten Hoof and Ulf Staginnus as company prepares to launch cancer drugs. ... The two additions follow the hire in July 2012 of Endocyte's first chief commercial officer, David Meek from

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editorial Director – Medical Education – Oxford: Negotiable

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Account Manager or AD - Medical Communications: Salary TBC

Scientific Director: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Programme Executive: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer: Great salary and benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager / Account Director: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...